CAMP4 Therapeutics (CAMP) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 8.2% versus a loss of 52.7%. Larimar Therapeutics is the larger company by market cap ($206.2 million vs $198.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | LRMR |
|---|---|---|
| Share price | $3.17 | $1.99 |
| Market cap | $198.93M | $206.21M |
| 1-day change | -8.12% | -0.25% |
| YTD return | -48.29% | -47.90% |
| 1-year return | +8.19% | -52.74% |
| 5-year return | — | -84.48% |
| EPS (TTM) | $-2.35 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.50M | — |
| Revenue growth (YoY) | +436.50% | — |
| Net income (latest FY) | $-80.40M | $-165.67M |
| Operating margin | -1502.43% | — |
| Net margin | -2298.54% | — |
| 52-week high | $7.75 | $6.42 |
| 52-week low | $2.88 | $1.92 |
| Distance from 52-week high | -59.10% | -69.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +233.44% | +625.44% |
| Average volume | 267.29K | 1.31M |
| Shares outstanding | 62.75M | 103.88M |
| Employees | 48 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed LRMR by 60.9 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
CAMP vs LRMR FAQ
Which is bigger, CAMP4 Therapeutics or Larimar Therapeutics?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $206.21M compared with $198.93M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or LRMR?
CAMP returned +8.19% over the past 12 months, compared with -52.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.